H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsOct 31 06:35 ET · Ratings

LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $33

Moomoo NewsOct 30 18:31 ET · Ratings

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Yahoo FinanceOct 20 09:10 ET

Companies Like Mineralys Therapeutics (NASDAQ:MLYS) Are In A Position To Invest In Growth

Simply Wall StOct 7 11:48 ET

Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension

BenzingaSep 25 08:31 ET

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Trial

TipRanksSep 25 08:28 ET